MDNA Life Sciences

MDNA Life Sciences is a life sciences company focused on developing liquid biopsy tests based on the mitochondrial genome to enhance clinical insights and treatment decisions for patients worldwide. The company’s current pipeline includes potential products for the diagnosis of prostate cancer and the detection of endometriosis. The company has also identified biomarkers based on mitochondrial DNA, which it believes are associated with ovarian and lung cancers, and intends to advance into the biomarker discovery phase for pancreatic, liver, breast, stomach, esophageal, and colorectal cancers.